Acadia Pharmaceuticals Stock Analysis
ACAD Stock | USD 16.29 0.08 0.49% |
ACADIA Pharmaceuticals is undervalued with Real Value of 20.03 and Target Price of 31.25. The main objective of ACADIA Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what ACADIA Pharmaceuticals is worth, separate from its market price. There are two main types of ACADIA Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The ACADIA Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and ACADIA Pharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.
ACADIA |
ACADIA Stock Analysis Notes
About 97.0% of the company shares are held by institutions such as insurance companies. The book value of ACADIA Pharmaceuticals was presently reported as 3.47. The company last dividend was issued on the 30th of June 2010. ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California. Acadia Pharmaceutica operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 540 people. For more info on ACADIA Pharmaceuticals please contact Stephen JD at 858 558 2871 or go to https://www.acadia.com.ACADIA Pharmaceuticals Quarterly Total Revenue |
|
ACADIA Pharmaceuticals Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. ACADIA Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding ACADIA Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
ACADIA Pharmaceuticals generated a negative expected return over the last 90 days | |
The company reported the previous year's revenue of 726.44 M. Net Loss for the year was (61.29 M) with profit before overhead, payroll, taxes, and interest of 145.49 M. | |
Over 97.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from investing.com: ACADIA shares reiterate outperform rating on recent in-licensing |
ACADIA Pharmaceuticals Upcoming and Recent Events
26th of February 2024 Upcoming Quarterly Report | View | |
13th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
26th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
ACADIA Largest EPS Surprises
Earnings surprises can significantly impact ACADIA Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2024-08-06 | 2024-06-30 | 0.18 | 0.2 | 0.02 | 11 | ||
2022-11-02 | 2022-09-30 | -0.19 | -0.17 | 0.02 | 10 | ||
2013-08-06 | 2013-06-30 | -0.09 | -0.11 | -0.02 | 22 |
ACADIA Pharmaceuticals Environmental, Social, and Governance (ESG) Scores
ACADIA Pharmaceuticals' ESG score is a quantitative measure that evaluates ACADIA Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of ACADIA Pharmaceuticals' operations that may have significant financial implications and affect ACADIA Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.
ACADIA Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Palo Alto Investors, Llc | 2024-09-30 | 2.5 M | First Trust Advisors L.p. | 2024-06-30 | 2.1 M | Tang Capital Management Llc | 2024-09-30 | 1.5 M | Norges Bank | 2024-06-30 | 1.5 M | Goldman Sachs Group Inc | 2024-06-30 | 1.3 M | Voloridge Investment Management, Llc | 2024-09-30 | 1.3 M | Man Group Plc | 2024-09-30 | 1.3 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.3 M | Connor Clark & Lunn Inv Mgmt Ltd | 2024-06-30 | 1.3 M | Baker Bros Advisors Lp | 2024-09-30 | 42.9 M | Vanguard Group Inc | 2024-09-30 | 13.8 M |
ACADIA Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.71 B.ACADIA Profitablity
The company has Profit Margin (PM) of 0.14 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.13 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.13.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.09) | (0.09) | |
Return On Capital Employed | (0.15) | (0.16) | |
Return On Assets | (0.08) | (0.09) | |
Return On Equity | (0.14) | (0.15) |
Management Efficiency
ACADIA Pharmaceuticals has return on total asset (ROA) of 0.0872 % which means that it generated a profit of $0.0872 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2736 %, meaning that it created $0.2736 on every $100 dollars invested by stockholders. ACADIA Pharmaceuticals' management efficiency ratios could be used to measure how well ACADIA Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of November 28, 2024, Return On Tangible Assets is expected to decline to -0.09. In addition to that, Return On Capital Employed is expected to decline to -0.16. At present, ACADIA Pharmaceuticals' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 5.4 M, whereas Net Tangible Assets are forecasted to decline to about 403.1 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 2.64 | 2.77 | |
Tangible Book Value Per Share | 2.24 | 2.35 | |
Enterprise Value Over EBITDA | (73.68) | (70.00) | |
Price Book Value Ratio | 11.88 | 12.47 | |
Enterprise Value Multiple | (73.68) | (70.00) | |
Price Fair Value | 11.88 | 12.47 | |
Enterprise Value | 1.7 B | 1.8 B |
Evaluating the management effectiveness of ACADIA Pharmaceuticals allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The ACADIA Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Operating Margin 0.1264 | Profit Margin 0.1383 | Beta 0.379 | Return On Assets 0.0872 | Return On Equity 0.2736 |
Technical Drivers
As of the 28th of November, ACADIA Pharmaceuticals owns the coefficient of variation of 2974.8, and Market Risk Adjusted Performance of 0.0511. ACADIA Pharmaceuticals technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the entity's future prices. Please confirm ACADIA Pharmaceuticals mean deviation, standard deviation, treynor ratio, as well as the relationship between the downside deviation and information ratio to decide if ACADIA Pharmaceuticals is priced adequately, providing market reflects its prevailing price of 16.29 per share. Given that ACADIA Pharmaceuticals has jensen alpha of (0.12), we suggest you to validate ACADIA Pharmaceuticals's latest market performance to make sure the company can sustain itself at some future date.ACADIA Pharmaceuticals Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. ACADIA Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for ACADIA Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
ACADIA Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ACADIA Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on ACADIA Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ACADIA Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ACADIA Pharmaceuticals Outstanding Bonds
ACADIA Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ACADIA Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ACADIA bonds can be classified according to their maturity, which is the date when ACADIA Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
Volcan Compania Minera Corp BondUSP98047AC08 | View | |
Boeing Co 2196 Corp BondUS097023DG73 | View | |
HSBC Holdings PLC Corp BondUS404280DR76 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
International Game Technology Corp BondUS460599AD57 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
MGM Resorts International Corp BondUS552953CD18 | View |
ACADIA Pharmaceuticals Predictive Daily Indicators
ACADIA Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ACADIA Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
ACADIA Pharmaceuticals Corporate Filings
8K | 20th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 7th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 15th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 25th of September 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 23rd of September 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
ACADIA Pharmaceuticals Forecast Models
ACADIA Pharmaceuticals' time-series forecasting models are one of many ACADIA Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ACADIA Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About ACADIA Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how ACADIA Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling ACADIA shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as ACADIA Pharmaceuticals. By using and applying ACADIA Stock analysis, traders can create a robust methodology for identifying ACADIA entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (0.07) | (0.07) | |
Operating Profit Margin | (0.10) | (0.11) | |
Net Loss | (0.08) | (0.09) | |
Gross Profit Margin | 0.94 | 0.98 |
Current ACADIA Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. ACADIA analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. ACADIA analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
31.25 | Buy | 20 | Odds |
Most ACADIA analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand ACADIA stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of ACADIA Pharmaceuticals, talking to its executives and customers, or listening to ACADIA conference calls.
ACADIA Stock Analysis Indicators
ACADIA Pharmaceuticals stock analysis indicators help investors evaluate how ACADIA Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading ACADIA Pharmaceuticals shares will generate the highest return on investment. By understating and applying ACADIA Pharmaceuticals stock analysis, traders can identify ACADIA Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow | 114.8 M | |
Common Stock Shares Outstanding | 163.8 M | |
Total Stockholder Equity | 431.8 M | |
Tax Provision | 10.2 M | |
Quarterly Earnings Growth Y O Y | 28.347 | |
Property Plant And Equipment Net | 56.5 M | |
Cash And Short Term Investments | 438.9 M | |
Cash | 188.7 M | |
Accounts Payable | 17.5 M | |
Net Debt | -131.5 M | |
50 Day M A | 15.6178 | |
Total Current Liabilities | 254.3 M | |
Other Operating Expenses | 799.8 M | |
Non Current Assets Total | 132.8 M | |
Forward Price Earnings | 22.5225 | |
Non Currrent Assets Other | 5.1 M | |
Stock Based Compensation | 66.4 M |
Complementary Tools for ACADIA Stock analysis
When running ACADIA Pharmaceuticals' price analysis, check to measure ACADIA Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ACADIA Pharmaceuticals is operating at the current time. Most of ACADIA Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ACADIA Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ACADIA Pharmaceuticals' price. Additionally, you may evaluate how the addition of ACADIA Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |